- Report
- March 2025
- 187 Pages
Global
From €3351EUR$3,545USD£2,847GBP
€3723EUR$3,939USD£3,164GBP
- Report
- February 2025
- 200 Pages
Global
From €4244EUR$4,490USD£3,606GBP
- Report
- February 2024
- 118 Pages
Global
From €3500EUR$3,967USD£3,078GBP
- Report
- April 2023
- 85 Pages
Global
From €3500EUR$3,967USD£3,078GBP
- Report
- April 2025
- 50 Pages
Global
From €2505EUR$2,650USD£2,128GBP
Sulfadiazine is an antibiotic used to treat a variety of bacterial infections. It belongs to a class of antibiotics known as sulfonamides, which are used to treat a wide range of infections, including urinary tract infections, skin infections, and respiratory infections. Sulfadiazine is often used in combination with other antibiotics to treat more serious infections. It is available in both oral and injectable forms.
Sulfadiazine is a commonly prescribed antibiotic, and is widely available in both generic and brand-name formulations. It is generally well-tolerated, with few side effects. However, it can cause allergic reactions in some people, and should be used with caution in those with a history of allergies.
The sulfadiazine market is highly competitive, with a number of companies offering generic and brand-name formulations. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. Show Less Read more